Knip M
University of Tampere, Department of Pediatrics, Tampere University Hospital, Finland.
Ann Med. 1997 Oct;29(5):447-51. doi: 10.3109/07853899708999375.
Insulin-dependent diabetes mellitus (IDDM) is a chronic autoimmune disease with a subclinical prodromal period characterized by selective destruction of insulin-producing beta cells in the pancreatic islets. This process is assumed to be T-cell mediated, but the emergence of disease-associated autoantibodies into the peripheral circulation is usually the first noticeable sign of beta-cell autoimmunity in human IDDM. Recent observations have suggested that beta-cell autoimmunity may be induced in any individual at any time. There are also data indicating that such autoimmunity may have been initiated prenatally in some individuals. Only a proportion of those with signs of islet cell autoimmunity progress to clinical disease, and harmless beta-cell autoimmunity reflected by positivity for a single autoantibody specificity seems to appear without any relation to genetic IDDM susceptibility. One can hypothesize that in most subjects HLA-conferred protection against IDDM prevents the beta-cell process from progressing to a stage of destructive insulitis that may lead to clinical disease. Environmental factors may trigger initial beta-cell damage and subsequently accelerate the destructive process. Non-HLA genes may also be involved in the regulation of the progression rate. Prospective observations of prediabetic individuals have revealed that IDDM-associated autoantibodies tend to appear sequentially, and that those who progress to clinical disease mount a strong humoral immune response to most known disease-associated antigens. This indicates that the immune response associated with beta-cell destruction is not purely T-helper 1 biased. Antigen-specific immunotherapy may in the future offer effective measures to intervene in preclinical IDDM to prevent end-stage insulitis. Substantially more data have to be generated, however, on the mechanisms, efficacy and safety of such therapy before it is possible to judge its clinical applicability.
胰岛素依赖型糖尿病(IDDM)是一种慢性自身免疫性疾病,有一个亚临床前驱期,其特征是胰岛中产生胰岛素的β细胞被选择性破坏。这个过程被认为是由T细胞介导的,但疾病相关自身抗体进入外周循环通常是人类IDDM中β细胞自身免疫的第一个明显迹象。最近的观察表明,β细胞自身免疫可能在任何个体的任何时候被诱发。也有数据表明,这种自身免疫可能在一些个体的产前就已启动。只有一部分有胰岛细胞自身免疫迹象的人会发展为临床疾病,而由单一自身抗体特异性阳性反映的无害β细胞自身免疫似乎与遗传性IDDM易感性无关。可以推测,在大多数受试者中,HLA赋予的对IDDM的保护作用可防止β细胞过程发展到可能导致临床疾病的破坏性胰岛炎阶段。环境因素可能引发最初的β细胞损伤,随后加速破坏过程。非HLA基因也可能参与疾病进展速度的调节。对糖尿病前期个体的前瞻性观察表明,与IDDM相关的自身抗体往往会依次出现,并且那些发展为临床疾病的人对大多数已知的疾病相关抗原有强烈的体液免疫反应。这表明与β细胞破坏相关的免疫反应并非纯粹偏向于辅助性T细胞1。未来,抗原特异性免疫疗法可能会提供有效的措施来干预临床前IDDM,以预防终末期胰岛炎。然而,在判断其临床适用性之前,还必须生成大量关于这种疗法的机制、疗效和安全性的数据。